Abnova (Taiwan) Corporation (4133.TW)
TWD 27.9
(-0.36%)
TWD 27.9
(-0.36%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 7.7 Million TWD | -29.21% |
| 2022 | 10.88 Million TWD | 44.13% |
| 2021 | 7.55 Million TWD | -52.98% |
| 2020 | 16.06 Million TWD | -9.27% |
| 2019 | 17.7 Million TWD | 4900.0% |
| 2018 | 354 Thousand TWD | -51.9% |
| 2017 | 736 Thousand TWD | -31.85% |
| 2016 | 1.08 Million TWD | -26.83% |
| 2015 | 1.47 Million TWD | 672.77% |
| 2014 | 191 Thousand TWD | -33.22% |
| 2013 | 286 Thousand TWD | -67.57% |
| 2012 | 882 Thousand TWD | -32.15% |
| 2011 | 1.3 Million TWD | -9.53% |
| 2010 | 1.43 Million TWD | -95.87% |
| 2009 | 34.79 Million TWD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 7.28 Million TWD | -5.42% |
| 2024 Q2 | 5.91 Million TWD | -18.78% |
| 2023 Q3 | 5.06 Million TWD | -25.11% |
| 2023 Q2 | 6.76 Million TWD | -22.43% |
| 2023 Q4 | 7.7 Million TWD | 52.05% |
| 2023 Q1 | 8.72 Million TWD | -19.85% |
| 2023 FY | 7.7 Million TWD | -29.21% |
| 2022 Q3 | 8.98 Million TWD | -2.17% |
| 2022 FY | 10.88 Million TWD | 44.13% |
| 2022 Q4 | 10.88 Million TWD | 21.09% |
| 2022 Q2 | 9.18 Million TWD | 41.86% |
| 2022 Q1 | 6.47 Million TWD | -14.23% |
| 2021 Q2 | 11.4 Million TWD | -20.65% |
| 2021 Q4 | 7.55 Million TWD | -27.67% |
| 2021 Q1 | 14.37 Million TWD | -10.49% |
| 2021 FY | 7.55 Million TWD | -52.98% |
| 2021 Q3 | 10.44 Million TWD | -8.46% |
| 2020 Q3 | 15.06 Million TWD | 26.45% |
| 2020 FY | 16.06 Million TWD | -9.27% |
| 2020 Q1 | 14.94 Million TWD | -15.54% |
| 2020 Q2 | 11.91 Million TWD | -20.32% |
| 2020 Q4 | 16.06 Million TWD | 6.63% |
| 2019 FY | 17.7 Million TWD | 4900.0% |
| 2019 Q4 | 17.7 Million TWD | 17.01% |
| 2019 Q3 | 15.12 Million TWD | -16.25% |
| 2019 Q1 | 20.89 Million TWD | 5801.98% |
| 2019 Q2 | 18.06 Million TWD | -13.55% |
| 2018 FY | 354 Thousand TWD | -51.9% |
| 2018 Q2 | 906 Thousand TWD | 1194.29% |
| 2018 Q3 | 1 Million TWD | 10.49% |
| 2018 Q1 | 70 Thousand TWD | -90.49% |
| 2018 Q4 | 354 Thousand TWD | -64.64% |
| 2017 Q4 | 736 Thousand TWD | -93.1% |
| 2017 Q2 | 913 Thousand TWD | -16.16% |
| 2017 FY | 736 Thousand TWD | -31.85% |
| 2017 Q1 | 1.08 Million TWD | 0.83% |
| 2017 Q3 | 10.66 Million TWD | 1067.91% |
| 2016 Q3 | 145 Thousand TWD | -72.43% |
| 2016 FY | 1.08 Million TWD | -26.83% |
| 2016 Q4 | 1.08 Million TWD | 644.83% |
| 2016 Q2 | 526 Thousand TWD | 10.97% |
| 2016 Q1 | 474 Thousand TWD | -67.89% |
| 2015 FY | 1.47 Million TWD | 672.77% |
| 2015 Q4 | 1.47 Million TWD | 343.24% |
| 2015 Q3 | 333 Thousand TWD | -72.23% |
| 2015 Q2 | 1.19 Million TWD | 175.0% |
| 2015 Q1 | 436 Thousand TWD | 128.27% |
| 2014 Q3 | 328 Thousand TWD | 44.49% |
| 2014 FY | 191 Thousand TWD | -33.22% |
| 2014 Q4 | 191 Thousand TWD | -41.77% |
| 2014 Q2 | 227 Thousand TWD | -36.24% |
| 2014 Q1 | 356 Thousand TWD | 24.48% |
| 2013 Q3 | 259 Thousand TWD | -63.11% |
| 2013 Q4 | 286 Thousand TWD | 10.42% |
| 2013 FY | 286 Thousand TWD | -67.57% |
| 2013 Q1 | 780 Thousand TWD | -11.56% |
| 2013 Q2 | 702 Thousand TWD | -10.0% |
| 2012 Q1 | 979 Thousand TWD | -24.69% |
| 2012 Q4 | 882 Thousand TWD | -30.06% |
| 2012 FY | 882 Thousand TWD | -32.15% |
| 2012 Q2 | 1.11 Million TWD | 14.2% |
| 2012 Q3 | 1.26 Million TWD | 12.79% |
| 2011 Q4 | 1.3 Million TWD | -7.41% |
| 2011 Q1 | 964 Thousand TWD | -32.92% |
| 2011 Q2 | 915 Thousand TWD | -5.08% |
| 2011 Q3 | 1.4 Million TWD | 53.44% |
| 2011 FY | 1.3 Million TWD | -9.53% |
| 2010 Q4 | 1.43 Million TWD | 0.0% |
| 2010 FY | 1.43 Million TWD | -95.87% |
| 2009 FY | 34.79 Million TWD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Apex Biotechnology Corp. | 180.83 Million TWD | 95.739% |
| Sinphar Pharmaceutical Co.,Ltd. | 1.94 Billion TWD | 99.604% |
| Panion & Bf Biotech Inc. | 727.83 Million TWD | 98.941% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 1.2 Billion TWD | 99.363% |
| GenMont Biotech Incorporation | 58.3 Million TWD | 86.784% |
| Adimmune Corporation | 3.14 Billion TWD | 99.755% |
| Tanvex BioPharma, Inc. | 1.73 Billion TWD | 99.555% |
| Polaris Group | 1.19 Billion TWD | 99.357% |
| Energenesis Biomedical CO.,LTD. | - TWD | -Infinity% |
| UnicoCell Biomed Co., Ltd. | 74.32 Million TWD | 89.632% |
| PELL Bio-Med Technology Co. Ltd. | 172.55 Million TWD | 95.534% |